6月2日，Praxis Precision Medicines盘中下跌15.36%，报283.47美元/股，成交额2.07亿美元。
消息面上，公司宣布其针对难治性局灶性发作癫痫的Power1研究未能达到预设的主要疗效终点，这一结果对公司核心管线构成重大挑战。尽管试验在次要终点方面取得一定进展——30毫克剂量组在降低癫痫发作频率方面展现出更为显著的效果，且新药Vormatrigine耐受性良好、因不良事件停药率低于10%，但主要终点的失败仍令市场信心受挫。对于临床阶段的生物制药公司而言，关键试验主要终点未达标通常意味着后续开发路径面临不确定性，市场对此反应剧烈。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.